Redo vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Utah post-purchase platform with a bundled coverage model; customers pay a checkout fee to unlock free returns, warranty, and package protection, self-funding merchant post-purchase costs.
About
Redo was founded in Pleasant Grove, Utah to bring a novel pricing model to the post-purchase experience category: instead of charging merchants per return or per shipment, Redo offers a bundled coverage product that merchants sell to customers at checkout as an optional add-on. Customers pay a small fee to unlock free returns, warranty protection, and package protection on their order, while Redo collects those fees and pays for the cost of returns and claims, creating a self-funding post-purchase operations model for the merchant.\n\nThe Redo platform handles the operational layer behind this coverage model, providing self-service returns portals, automated exchange workflows, warranty claim management, and package protection claims processing. For merchants, the value proposition is a meaningful reduction in net return costs if claim rates are lower than expected, and a fully funded returns operation if take rates on the coverage add-on are high enough to cover processing costs entirely.\n\nRedo targets Shopify-native DTC brands that are looking for an alternative to traditional returns management platforms, particularly those with higher average order values and product categories where warranty and package protection are credible value-adds to customers. The company competes against Loop Returns and AfterShip Returns in the returns management category while occupying a distinct business model niche with its customer-funded coverage approach.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.